Filing Flows › Comparisons › NVAX vs KYMR
Novavax vs Kymera Therapeutics: NVAX and KYMR compared
Novavax is the larger company: $68.3M of revenue in its latest quarter (Q3 2026) against $65.0M for Kymera Therapeutics (Q2 2026). Kymera Therapeutics is growing faster (+466% against -3% a year earlier). Novavax is more profitable, with an operating margin of -45.8% against -116.3%.
Where the money goes: NVAX and KYMR
Novavax (NVAX) · Q3 2026
Novavax, Q3 2026: revenue $68.3M (-3% year over year), operating margin -45.8%, net loss $31.4M, operating cash flow −$94.2M. The chart follows the revenue to costs, profit and cash.
Kymera Therapeutics (KYMR) · Q2 2026
Kymera Therapeutics, Q2 2026: revenue $65.0M (+466% year over year), operating margin -116.3%, net loss $61.2M, operating cash flow −$54.1M. The chart follows the revenue to costs, profit and cash.
| Novavax (NVAX) | Kymera Therapeutics (KYMR) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $68.3M | $65.0M |
| Revenue growth, Y/Y | -3% | +466% |
| Operating margin | -45.8% | -116.3% |
| Net earnings | −$31.4M | −$61.2M |
| Net margin | -45.9% | -94.2% |
| Operating cash flow | −$94.2M | −$54.1M |
Where the revenue comes from
Novavax
- Licensing, royalties, and other: $42.6M (62%)
- Product sales: $25.7M (38%)
Questions
Which is bigger, Novavax or Kymera Therapeutics?
Novavax is the larger company: $68.3M of revenue in its latest quarter (Q3 2026) against $65.0M for Kymera Therapeutics (Q2 2026).
Is Novavax or Kymera Therapeutics growing faster?
Kymera Therapeutics is growing faster (+466% against -3% a year earlier).
Which is more profitable, Novavax or Kymera Therapeutics?
Novavax is more profitable, with an operating margin of -45.8% against -116.3%.
More: Novavax earnings · how Novavax makes money · Kymera Therapeutics earnings · how Kymera Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 5, 2026). Fiscal quarters can end on different dates. Not investment advice.